Parkinson’s Awareness Month

M3 Global Research is currently recruiting patients with Parkinson’s to participate in usability testing for a new device used in conjunction with a smart phone (both provided) in the United States and in Germany. We’re offering generous compensation to the patients taking part and also the physicians referring them. If you are a member of the M3 Global Research panel, contact M3_US_support@eu.m3.com to find out if you qualify. If you are a patient who is not a member and wish to participate, please register by clicking here if you are in the USA and here if you are in Germany. You will then receive an invite by email.

Around seven to 10 million people worldwide live with Parkinson’s disease, a condition that currently has no cure. For this year’s WordParkinson’s Day, Parkinson’s UK, a charity that works towards finding a cure and improving life for everyone affected by the condition, has launched the campaign #UniteForParkinsons. It aims to give voice and platform to the Parkinson’s community by featuring their experiences in a world-wide campaign video and encouraging others to do the same. Watch it here:


Complexity of Parkinson’s ‘massively underestimated’ in the UK

In a survey to mark World Parkinson’s Day (Wednesday 11 April), Parkinson’s UK has discovered that 78% of the public massively underestimate how many symptoms of Parkinson’s there are. Although most people are aware of visible symptoms like tremor, Parkinson’s can also come with more than 40 less well-known symptoms such as sleep issues, anxiety and hallucinations. Shockingly, more than a third (37%) thought there were fewer than ten symptoms of Parkinson’s and more than 41% thought there were fewer than 30.

The charity is warning that this lack of awareness means that people with Parkinson’s often feel they need to hide their symptoms in public, or don’t want to go out at all due to being incorrectly judged or mocked. Previous findings from the charity have uncovered:

  • A quarter (25%) have had symptoms mistaken for drunkenness
  • 11% have been laughed at because of their symptoms
  • More than a third (34%) feel they would be judged if they were out in public
  • Almost a third (32%) don’t feel like their symptoms are socially acceptable

These symptoms are merely the tip of the iceberg, it warns, and do not reflect what people with Parkinson’s most want addressing. In a recent project carried out by the charity to identify priorities to focus on for improving everyday life, tremor came 26th on a list of what people with Parkinson’s want research to tackle.

Artificial intelligence to help develop new Parkinson’s treatments

Parkinson’s UK is actively involved in research, and recently one of its research proposals has won the BenevolentAI Award. The project demonstrated how AI technology could solve specific research challenges in Parkinson’s.

There have been no major breakthroughs in Parkinson’s treatments in the last 50 years. Current treatments revolve around medication that works by restoring the level of dopamine in the brain or mimicking its actions; deep brain stimulation (DBS), a type of surgery where electrodes are implanted deep inside specific parts of the brain, but which is not suitable for every patient; and physical therapies such as physiotherapy, speech and language therapy and occupational therapy, that are important in the management of the condition.

Parkinson’s UK’s proposal will use BenevolentAI platform’s capabilities to reason, deduce and suggest entirely new treatments for Parkinson’s. The aim is to identify at least three currently available medicines that can be repurposed to address Parkinson’s, and two brand-new ways to treat the condition with new drugs. Read more about the project: Artificial intelligence to help develop new Parkinson’s treatments.

*All rights belong to Parkinson’s UK. We would like to thank the charity for sharing this content with us.

Bullying, undermining and harassment at work

August’s Monthly Pulse question was about bullying, undermining and harassment at work. Around one in five doctors in the UK’s NHS say they have been bullied or harassed in the workplace, with the British Orthopaedic Trainee Association (BOTA) reporting that 73% trainees had witnessed bullying, undermining or harassment at work. Most incidents go unreported, often because staff are afraid to raise concerns or they believe nothing will happen. This situation seems to be a common issue worldwide.

BOTA‘s #HammerItOut campaign, which aims to highlight the issue, uses the following definitions: Undermining is behaviour that subverts, weakens or wears away confidenceBullying is behaviour that hurts or frightens someone who is less powerful, often forcing them to do something they do not want to do. Bullying and harassment means any unwanted behaviour that makes someone feel intimidated, humiliated or offended.

The question we delivered to our medical community in August was the following:

Have you ever experienced or witnessed bullying, undermining or harassment at work?

In Europe the analysis was conducted amongst 5,016 M3 members in the UK, France, Germany, Italy and Spain. 65% of the healthcare professional surveyed have experienced or witnessed bullying, undermining and harassment at work. Bulling and harassment was most prevalent in the UK and France at 78% and 73% respectively. On the other hand, Italy has the lowest incidence.

The cross-continental analysis shows that 73% of healthcare professionals surveyed in USA have witnessed the same situation. Bullying and harassment was most prevalent in Canada at 85% while Europe has the lowest incidence at 35%.

By registering with M3 Global Research you will receive the Monthly Pulse directly to your inbox and you will be able to give your personal opinion about relevant healthcare related issue and compare your thoughts with your colleagues around the World.

harassment at work

Monthly Pulse

 

Universal healthcare coverage

Universal healthcare coverage was the Monthly Pulse topic we sent out to our consumer panel members’ in August.

Healthcare reform has long since been a major policy area commanding attention in the United States and around the world. Crucial to the debate are the various plans that have been proposed to repeal and replace the existing Affordable Care Act, better known as “Obamacare”.

By contrast, European countries offer universal healthcare coverage to their citizens independent of their financial situation – something the United States’ government moved towards with Obamacare.

We asked the M3 Global Research panel if they think universal healthcare coverage, where everyone has access to quality health services and is protected against financial risk, should be available and mandated for everyone in the United States.

The survey was conducted amongst 2,895 M3 Global Research panel members in the USA. The results in the USA show that the majority (80%) agree that universal healthcare cover should be available and mandated for everyone in the United States.

USA_PatientsAugustMonthlyQuestion

By registering with M3 Global Research you will receive the Monthly Pulse directly to your inbox and you will be able to give your opinion about relevant healthcare related issue and compare your thoughts with your colleagues around the World.

Overuse of unnecessary antibiotics

The overuse of unnecessary antibiotics has been the topic of the Monthly pulse we delivered to our panel members’ inboxes in July. In the UK it is estimated that 1.6 million unnecessary antibiotic prescriptions are issued each year and this issue is not exclusive to the UK.

Patients are used to visiting the GP whenever they suffer from illnesses like upper respiratory tract infections and often they expect to be prescribed antibiotic treatment, regardless of the efficacy.

Consequently, 70% of bacteria have now developed resistance to antibiotics as a result of overuse, which is now leading to the development of new strains of antibiotic-resistant bacteria.

We asked our community where the responsibility of raising awareness about antibiotic overuse lies – with the prescribing physician, or with healthcare institutions and/or governmental bodies?

The survey was conducted amongst 15,875 M3 members in Europe (Uk, France, Italy, Spain and Germany), Canada and USA.

The results in Canada, Europe and USA are similar. More than 90% in from the threes respondent groups agree that is the responsibility of the physician to reduce unnecessary antibiotic use.

In Europe, 93% of the healthcare professionals surveyed in the UK, Germany, France, Spain, and Italy think that it is the responsibility of the physician to reduce unnecessary antibiotic use. Spanish and Italian respondents, at 95%, are the most supportive of this view. Conversely, with 85% in favour, French doctors are the least supportive.

By registering with M3 Global Research you will receive the Monthly Pulse directly to your inbox and you will be able to give your opinion about relevant healthcare related issue and compare your thoughts with your colleagues around the World.

overuse of unnecessary antibiotics

 

overuse of unnecessary antibiotics

Haematologists needed – ‘Real World’ study on Haemophilia

This month we are very pleased to present a special study on Haemophilia. This study will be using a methodology known as ‘Real World’. This methodology is becoming increasingly important as it provides a truly in-depth analysis of the chosen subject matter by involving both the treaters and those receiving the treatment. This in turn allows us to gain a better understanding of the needs and challenges encountered by the physicians and patients alike.

We are looking for haematologists who treat this disorder in UK, US, France, Germany, Italy and Spain.

The total incentive of this study will be up to £1000/$1000/1000€.

Would you like to participate?

Register today

These are some of the benefits of this particular type of studies that respondents will benefit from:

  • High profile haemophilia Patient Outcome
  • Results will be used to ensure the best possible treatment guidelines
  • The results will be published in peer-review journals and presented at key conferences 
  • Your opinions and insights will directly lead to improvement in patients treatments and quality of life
  • Pharmaceutical companies increase focus on patients and regulators look towards real world patient outcomes to support decisions

Phases of the study:

Haematologist needed

Please click here to have further information about this study.

united-states (3) REAL WORLD_Patient Outcome Survey

italy (1) REAL WORLD_Patient Outcome Survey

spain (2) REAL WORLD_Patient Outcome Survey

germany (2) REAL WORLD_Patient Outcome Survey

france (1) REAL WORLD_Patient Outcome Survey

Click on the following links to visualise previous papers published in medical journals from other Real World studies:

“Quality of Life of Patients With Alzheimer’s Disease” presented at ISPOR 19th Annual European Congress (2016)

“Patient-reported Symptom Burden Among Relapsing-Remitting Multiple Sclerosis (RRMS) vs Secondary Progressive Multiple Sclerosis Patients (SPMS) in Europe” presented at 1st Congress of the European Academy of Neurology

We invite you to register today and participate in this study. Your participation will directly lead to improvement in patients treatments.

The M3 Global Research Team